FDA OKs AbbVie/Genentech/AstraZeneca Drug Combo in First-Line CLL
By Colin Kellaher
AbbVie and Genentech have won expanded Food and Drug Administration approval of their Venclexta cancer drug in combination with AstraZeneca's Calquence for previously untreated adults with chronic lymphocytic leukemia, or CLL.
The three companies on Friday said the FDA green light makes the combination the first and only all-oral, fixed-duration regimen in the first-line setting for patients with CLL, one of the most common forms of leukemia in adults.
The North Chicago, Ill., biopharmaceutical company and Genentech, a unit of Swiss drug giant Roche Holding, are jointly developing Venclexta. The drug is jointly marketed by AbbVie and Genentech in the U.S., and by AbbVie alone outside the U.S.
Venclexta and Calquence were already approved separately around the world for adults with CLL or small lymphocytic lymphoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 20, 2026 06:44 ET (11:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
United States